Skip to content
‹ Back to IndustriesSciences

Embracing the Human Side of Healthcare Labs

Deanna Shukis from Psyche Systems discusses the importance of quality software in healthcare labs. She highlights the human aspect of lab work, emphasizing how lab results impact patients' lives. Shukis also shares insights on the development of a comprehensive lab information system to address evolving industry needs.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Promoted Content · · ClinicDeanna Shukis PodcastHealthcareLaboratory
Share
Embracing the Human Side of Healthcare Labs

Key takeaways

01

Quality software is essential for efficient and impactful lab work in healthcare.

02

Labs must view specimens as human lives, acknowledging the impact of their work on patient outcomes.

03

Psyche Systems developed a versatile lab information system that integrates molecular diagnostics, DNA sequencing, and toxicology.

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

The importance of labs in healthcare is vital. Lab work helps clinicians understand and diagnose patients, and for labs to work smoothly and give feedback that can potentially change lives, they need quality software. Today, we’re joined by Deanna Shukis, M.S., CT(ASCP), senior application and implementation specialist for Psyche Systems, a company that creates lab information systems (LIS) that enable pathologists, physicians, and medical labs to streamline the delivery of vital medical results.

Shukis, a former cytotechnologist, talks with us today about the concept, “Life is a Case,” examining the real end results when it comes to improving a patient’s health or even saving a life.

Though the lab is very clinical, Shukis shared that what happens in the lab isn’t about numbers on a barcode. “There is actually a lot of humanization in the lab. Yes, there are just numbers and data on the specimens, but ultimately, those in the lab know that this specimen is a person, a human life, and what happens with the results will impact their life,” she said.

“The ‘Life of a Case’ diagram follows all the steps needed from ordering, collecting, transporting, and analysis. The ‘case’ follows steps, and each step must be completed successfully to move forward. It’s about checks and balances to meet regulatory compliance but also the perspective of care and concern because these results could possibly change patient’s life,” Shukis said.

Deanna also talked about the software the Psyche team developed about six years ago to meet the needs of a changing industry. “The industry was evolving, especially with the need for molecular diagnostic components, which were missing. We met with clients and did much research internally to develop something that addressed not only molecular diagnostic components but also more areas like DNA sequencing and toxicology,” she said.

“The new software also enables versatility for all lab operations. Previously, different labs would do their analysis and prepare a report for the physician, so then he or she may have had multiple reports to understand the results. Our software covers all areas and creates a comprehensive report for doctors so they can then develop a plan for the patient’s future.”

Find out more about how Psyche developed the software and is playing a focused role in patient care by listening to the podcast.

Follow us on social media for the latest updates in B2B!

Twitter – @EnergyMKSL

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

PC
Promoted Content
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Antibody developability checks are moving into discovery instead of waiting for development

Antibody developability checks are moving into discovery instead of waiting for development

Maria Gonzalez-Pajuelo of FairJourney Bio says the order in antibody discovery is changing: developability has become a much more important consideration during discovery, rather than an issue left until later-stage development. The goal, she says, is that what comes out of discovery is something CMC can take forward easily.

  • 01Discovery-stage developability screens can rank many antibodies tested once or twice and may reduce surprises later in development, while development still focuses on several lots of a single antibody and answers different questions.

Oct 1, 2026

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

ISPE’s 2026 Annual Meeting and Expo in Washington, DC organizes its program around five tracks running from discovery to governance, with international program committee chair Connie Langer of Pfizer Global Supply and executive chair Jose Caraballo of JCO Global Advisory LLC describing how the tracks connect—and why AI is treated as a cross-cutting topic rather than a standalone track. Deloitte’s December 2025 survey of 280 executives frames the mood the program is built for.

  • 01ISPE’s 2026 Annual Meeting has no dedicated AI track; executive chair Jose Caraballo expects AI presentations across all five tracks, from discovery to governance.
  • 02Deloitte’s December 2025 survey of 280 biopharma and medtech C-suite executives found more than 75% confident in their own outlook but only 41% optimistic about the global economy, a mood the story says the ISPE chairs are programming for.
  • 03A staffing firm reports life sciences job openings falling even as digital fluency becomes a required skill, so the upskilling burden lands on the people already employed, which is where the mandatory, university-partnered AI training Connie Langer describes at her company sits.

Sep 30, 2026

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site designs preclinical tumor models to match specific therapies and delivery routes, rather than forcing treatments into standard study designs. It combines custom surgical procedures, cell line-derived xenografts, patient-derived xenografts (including post-treatment models), and biomarker capabilities to generate translational data that can help sponsors decide whether to advance a program.

  • 01Orthotopic brain tumor implantation using tagged models lets researchers track tumor growth in the original organ, aligning the model and delivery route with how therapies are intended to be tested.
  • 02Patient-derived xenografts developed from tumors after prior treatment may better reflect progressed disease, helping teams study therapies aimed at patients whose cancer has advanced after earlier treatment.
  • 03Combining biomarker analysis of preclinical model samples with clinical sample testing at one site could make it easier to connect what is measured in animals with what is later measured in patients.

Sep 30, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

PC
Promoted Content

Senior Application and Implementation Specialist at Psyche Systems

Deanna Shukis, M.S., CT(ASCP) is a senior application and implementation specialist at Psyche Systems. With a background as a former cytotechnologist, she works on developing and implementing lab information systems. Her expertise includes enhancing lab operations and patient care through quality software solutions.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512